Leronlimab vs Maraviroc
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: CCR5 co-receptor · full HIV pipeline
Leronlimab
Developed by CytoDyn
NCT02859961 · Phase 2/3 · completed
Although participants were randomized to dose groups, the study was open-label with no blinding and had no placebo or active-drug control arm - all arms received leronlimab, just at different doses, so there was no true comparator to establish efficacy against. The primary result was reported as simple percentages per dose group with no significance testing, and over half of enrolled participants discontinued before week 48, so this cannot be read as controlled evidence that leronlimab prevents virologic failure better than an alternative.
Reported efficacy
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77% (met)
Result source: NCT02483078
Maraviroc · Selzentry / Celsentri
Marketed by GlaxoSmithKline
NCT00098293 · Phase 3 · completed
This was a large, randomized, quadruple-blind, active-controlled trial comparing maraviroc with efavirenz, but its primary viral-load results were mixed rather than consistently meeting the prespecified non-inferiority margins. The primary endpoint was a virologic surrogate, and the once-daily maraviroc arm was terminated early after an interim analysis found that non-inferiority criteria were not met.
Next expected readout: March 2027 · NCT06805656 (registry estimate)
Reported efficacy
Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population; Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3% (mixed)
Result source: NCT00098293
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Leronlimab | Maraviroc |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | 41.8% vs 16.1%+25.7 vs placeboNCT0009830616 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | —Not reported | 112.5 vs 54.0+58.6 vs placeboNCT0009830619 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Leronlimab
- —Not reported
- Maraviroc
- 41.8% vs 16.1%+25.7 vs placeboNCT00098306
16 other results
- 46.8% vs 16.1% NCT00098306
- 45.0% vs 17.6% NCT00098722
- 44.5% vs 17.6% NCT00098722
- 42.2% vs 24.6% NCT00098306
- 48.5% vs 24.6% NCT00098306
- 45.6% vs 20.9% NCT00098722
- 40.8% vs 20.9% NCT00098722
- 74.6% vs 83.6% NCT00827112
- 67.8% vs 82.0% NCT00827112
- 76.3% vs 83.6% NCT00827112
- 74.6% vs 82.0% NCT00827112
- 67.8% vs 85.3% NCT00827112
- 74.6% vs 83.6% NCT00827112
- 81.4% vs 88.5% NCT00827112
- 79.7% vs 88.5% NCT00827112
- 81.4% vs 88.5% NCT00827112
HIV-1 RNA 50 copies/mL or more (week 48)
- Leronlimab
- —Not reported
- Maraviroc
- —Not reported
CD4 count, change (week 48)
- Leronlimab
- —Not reported
- Maraviroc
- 112.5 vs 54.0+58.6 vs placeboNCT00098306
19 other results
- 122.4 vs 54.0 NCT00098306
- 121.5 vs 69.3 NCT00098722
- 127.8 vs 69.3 NCT00098722
- 106.6 vs 52.1 NCT00098306
- 111.1 vs 52.1 NCT00098306
- 111.7 vs 63.8 NCT00098722
- 101.9 vs 63.8 NCT00098722
- 65.9 vs 51.3 NCT00098748
- 78.9 vs 51.3 NCT00098748
- 59.2 vs 36.4 NCT00098748
- 62.7 vs 36.4 NCT00098748
- 183.8 vs 171.5 NCT00098293
- 206.3 vs 171.5 NCT00098293
- 172.5 vs 143.5 NCT00098293
- 169.5 vs 143.5 NCT00098293
- 17 vs 17 NCT00735072
- 287.5 vs 298.5 NCT00827112
- 215.7 vs 226.6 NCT00827112
- 188.9 vs 173.3 NCT00827112
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Leronlimab: 7 of 8 rows · Maraviroc: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Leronlimab Rows use multiple source trials | Maraviroc Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 7.6 cells/uL700 mg Weekly Injectionsa,b,c,d,e NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 show 2 more doses-7.4 cells/uL525 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 -41.1 cells/uL350 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 | 93 cells/uL @ 144wkb,c,d,e NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy |
| HIV-1 RNA absolute change · log Induction | 0.6 vs 0.1 placebo log @ 1wkf,c,g,h NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3 | -89859.1 vs -107684.6 Atazanavir / Ritonavir + Emtricitabine / Tenofovir log @ 16wkf,c,g,h NCT00827112 · Phase 2 · registry result, not featured evidence · combination |
| HIV-1 RNA absolute change · log No placebo or comparator arm | 2.4 log @ 25wkb,c,i,j NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 1 other source trial-1.78 log350 mg weekly SQ NCT02175680 · Phase 2 · registry result, not featured evidence | -1.5 log @ 84wkb,c,i,j NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy |
| Time to Virologic Failure time to event · months No placebo or comparator arm | 2.32 months*350 mgk,c,l,e NCT02175680 · Phase 2 · registry result, not featured evidence · converted to months from 70.71 days as posted | 8.38 months*k,c,l,e NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy · converted to months from 255 days as posted 1 other source trial2.84 months* NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy · converted to months from 86.5 days as posted |
| Dropout rate | —700 mg Weekly Injectionsm NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 show 13 more results—525 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —350 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —Part 2 - Group A NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —Part 2 - Group B NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 0%PRO 140 NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3 —Part 2 PRO 140 Open Label for 24 W NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 —weekly for 1 week NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 4.7%350 mg weekly SQ NCT02175680 · Phase 2 · registry result, not featured evidence —Leronlimab NCT02175680 · Phase 2 · registry result, not featured evidence 0%PRO 140 Dose 1 NCT00110591 · Phase 1 · registry result, not featured evidence 0%PRO 140 Dose 2 NCT00110591 · Phase 1 · registry result, not featured evidence 0%PRO 140 Dose 3 NCT00110591 · Phase 1 · registry result, not featured evidence 0%PRO 140 Dose 4 NCT00110591 · Phase 1 · registry result, not featured evidence | —Once daily, then twice dailyn NCT00098293 · Phase 3 · combination · HIV · phase 3 show 29 more results45.1%Twice daily NCT00098293 · Phase 3 · combination · HIV · phase 3 —Twice daily NCT00098293 · Phase 3 · combination · HIV · phase 3 n/a: no completion milestoneBID NCT00098306 · Phase 2/3 · HIV · phase 2/3 —BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 —BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 n/a: no completion milestoneQD NCT00098306 · Phase 2/3 · HIV · phase 2/3 — NCT02881762 · Phase 4 · registry result, not featured evidence 0% NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy 0% NCT00925756 · Phase 4 · registry result, not featured evidence 16.9% NCT01275625 · Phase 4 · registry result, not featured evidence · combination 27.3%Maraviroc PLUS Raltegravir in Comb NCT00870363 · Phase 4 · registry result, not featured evidence · combination 0%Maraviroc in Combination With 2 NR NCT00870363 · Phase 4 · registry result, not featured evidence · combination 4.3% NCT00735072 · Phase 4 · registry result, not featured evidence 28.6% NCT01896921 · Phase 3 · registry result, not featured evidence · combination 7.7% NCT00844519 · Phase 3 · registry result, not featured evidence 40.2% NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy 12.5% NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy 12.5% NCT01154673 · Phase 2/3 · registry result, not featured evidence —BID NCT00098722 · Phase 2/3 · registry result, not featured evidence —QD NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy 3.2%BID NCT00098748 · Phase 2/3 · registry result, not featured evidence 0%QD NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy 12.2% NCT02741323 · Phase 2 · registry result, not featured evidence 46.2% NCT01276236 · Phase 2 · registry result, not featured evidence 20% NCT00987948 · Phase 2 · registry result, not featured evidence 12% NCT00993148 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT00827112 · Phase 2 · registry result, not featured evidence · combination 6.7% NCT01894776 · Phase 1 · registry result, not featured evidence 7.7% NCT00982878 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —700 mg Weekly Injectionsm NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 show 13 more results—525 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —350 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —Part 2 - Group A NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —Part 2 - Group B NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —PRO 140 NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3 —Part 2 PRO 140 Open Label for 24 W NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 —weekly for 1 week NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 —350 mg weekly SQ NCT02175680 · Phase 2 · registry result, not featured evidence —Leronlimab NCT02175680 · Phase 2 · registry result, not featured evidence —PRO 140 Dose 1 NCT00110591 · Phase 1 · registry result, not featured evidence —PRO 140 Dose 2 NCT00110591 · Phase 1 · registry result, not featured evidence —PRO 140 Dose 3 NCT00110591 · Phase 1 · registry result, not featured evidence —PRO 140 Dose 4 NCT00110591 · Phase 1 · registry result, not featured evidence | —Once daily, then twice dailyn NCT00098293 · Phase 3 · combination · HIV · phase 3 show 29 more results7.3%Twice daily NCT00098293 · Phase 3 · combination · HIV · phase 3 —Twice daily NCT00098293 · Phase 3 · combination · HIV · phase 3 4.2%BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 —BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 —BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 4.6%QD NCT00098306 · Phase 2/3 · HIV · phase 2/3 — NCT02881762 · Phase 4 · registry result, not featured evidence — NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy — NCT00925756 · Phase 4 · registry result, not featured evidence 5.2% NCT01275625 · Phase 4 · registry result, not featured evidence · combination —Maraviroc PLUS Raltegravir in Comb NCT00870363 · Phase 4 · registry result, not featured evidence · combination —Maraviroc in Combination With 2 NR NCT00870363 · Phase 4 · registry result, not featured evidence · combination — NCT00735072 · Phase 4 · registry result, not featured evidence — NCT01896921 · Phase 3 · registry result, not featured evidence · combination 3.8% NCT00844519 · Phase 3 · registry result, not featured evidence 2.4% NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy 2.2% NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy — NCT01154673 · Phase 2/3 · registry result, not featured evidence —BID NCT00098722 · Phase 2/3 · registry result, not featured evidence —QD NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy —BID NCT00098748 · Phase 2/3 · registry result, not featured evidence —QD NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy — NCT02741323 · Phase 2 · registry result, not featured evidence — NCT01276236 · Phase 2 · registry result, not featured evidence — NCT00987948 · Phase 2 · registry result, not featured evidence — NCT00993148 · Phase 2 · registry result, not featured evidence · combination 3.1% NCT00827112 · Phase 2 · registry result, not featured evidence · combination — NCT01894776 · Phase 1 · registry result, not featured evidence — NCT00982878 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 5.3%700 mg Weekly Injectionsm NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 show 13 more results5.9%525 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 7.1%350 mg Weekly Injections NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 5.8%Part 2 - Group A NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 4.6%Part 2 - Group B NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 —PRO 140 NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3 15.4%Part 2 PRO 140 Open Label for 24 W NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 0%weekly for 1 week NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 —350 mg weekly SQ NCT02175680 · Phase 2 · registry result, not featured evidence 2.3%Leronlimab NCT02175680 · Phase 2 · registry result, not featured evidence 25%PRO 140 Dose 1 NCT00110591 · Phase 1 · registry result, not featured evidence 0%PRO 140 Dose 2 NCT00110591 · Phase 1 · registry result, not featured evidence 0%PRO 140 Dose 3 NCT00110591 · Phase 1 · registry result, not featured evidence 0%PRO 140 Dose 4 NCT00110591 · Phase 1 · registry result, not featured evidence | 27%Once daily, then twice dailyn NCT00098293 · Phase 3 · combination · HIV · phase 3 show 29 more results21.4%Twice daily NCT00098293 · Phase 3 · combination · HIV · phase 3 3.1%Twice daily NCT00098293 · Phase 3 · combination · HIV · phase 3 22.6%BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 0%BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 10.1%BID NCT00098306 · Phase 2/3 · HIV · phase 2/3 18.1%QD NCT00098306 · Phase 2/3 · HIV · phase 2/3 11.1% NCT02881762 · Phase 4 · registry result, not featured evidence 0% NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy 3.1% NCT00925756 · Phase 4 · registry result, not featured evidence 2.6% NCT01275625 · Phase 4 · registry result, not featured evidence · combination 0%Maraviroc PLUS Raltegravir in Comb NCT00870363 · Phase 4 · registry result, not featured evidence · combination 0%Maraviroc in Combination With 2 NR NCT00870363 · Phase 4 · registry result, not featured evidence · combination 0% NCT00735072 · Phase 4 · registry result, not featured evidence 42.9% NCT01896921 · Phase 3 · registry result, not featured evidence · combination 3.8% NCT00844519 · Phase 3 · registry result, not featured evidence 16.5% NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy 13.5% NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy 6.3% NCT01154673 · Phase 2/3 · registry result, not featured evidence 24.1%BID NCT00098722 · Phase 2/3 · registry result, not featured evidence 22%QD NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy 22.6%BID NCT00098748 · Phase 2/3 · registry result, not featured evidence 20.6%QD NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy 75.5% NCT02741323 · Phase 2 · registry result, not featured evidence 0% NCT01276236 · Phase 2 · registry result, not featured evidence 6.7% NCT00987948 · Phase 2 · registry result, not featured evidence 0% NCT00993148 · Phase 2 · registry result, not featured evidence · combination 21.7% NCT00827112 · Phase 2 · registry result, not featured evidence · combination 0% NCT01894776 · Phase 1 · registry result, not featured evidence 0% NCT00982878 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 700 mg Weekly Injectionsm upper respiratory tract infection 6.9% headache 4.6% diarrhoea 3.8% NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 show 11 more results525 mg Weekly Injections upper respiratory tract infection 6.8% diarrhoea 4.4% headache 4.4% NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 350 mg Weekly Injections diarrhoea 8.8% upper respiratory tract infection 8.8% fatigue 8.4% NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 upper respiratory tract infection 17.4% viral upper respiratory tract infection 14.5% diarrhoea 8.7% NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 upper respiratory tract infection 18.5% diarrhoea 9.2% headache 7.7% NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 diarrhoea 11.5% (placebo 0%) arthralgia 9.6% (placebo 0%) injection site haemorrhage 9.6% (placebo 3.7%) NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 weekly for 1 week fatigue 4% (placebo 0%) nausea 4% (placebo 0%) abdominal pain 0% (placebo 0%) NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 diarrhoea 9.3% fatigue 9.3% injection site pruritus 9.3% NCT02175680 · Phase 2 · registry result, not featured evidence back pain 25% (placebo 25%) cough 25% (placebo 0%) electrocardiogram t wave inversion 25% (placebo 0%) NCT00110591 · Phase 1 · registry result, not featured evidence abdominal pain upper 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 25%) aspartate aminotransferase increased 0% (placebo 50%) NCT00110591 · Phase 1 · registry result, not featured evidence pharyngolaryngeal pain 75% (placebo 0%) headache 50% (placebo 25%) abdominal pain upper 25% (placebo 0%) NCT00110591 · Phase 1 · registry result, not featured evidence high creatine phosphokinase level 50% (placebo 50%) cough 25% (placebo 0%) dizziness 25% (placebo 0%) NCT00110591 · Phase 1 · registry result, not featured evidence | Once daily, then twice dailyn nausea 34.5% diarrhoea 26.4% headache 25.3% NCT00098293 · Phase 3 · combination · HIV · phase 3 show 22 more resultsTwice daily nausea 38.3% headache 30.3% diarrhoea 25% NCT00098293 · Phase 3 · combination · HIV · phase 3 Twice daily abdominal distension 0% abdominal pain 0% abdominal pain upper 0% NCT00098293 · Phase 3 · combination · HIV · phase 3 BID diarrhoea 22.6% (placebo 25.4%) nausea 20.4% (placebo 19.5%) fatigue 19.6% (placebo 18.6%) NCT00098306 · Phase 2/3 · HIV · phase 2/3 BID abdominal distension 0% (placebo 3.4%) abdominal pain 0% (placebo 0.8%) arthralgia 0% (placebo 2.5%) NCT00098306 · Phase 2/3 · HIV · phase 2/3 BID upper respiratory tract infection 5.8% (placebo 8.5%) abdominal distension 0% (placebo 3.4%) abdominal pain 0% (placebo 0.8%) NCT00098306 · Phase 2/3 · HIV · phase 2/3 QD diarrhoea 25% (placebo 25.4%) nausea 19.4% (placebo 19.5%) fatigue 15.5% (placebo 18.6%) NCT00098306 · Phase 2/3 · HIV · phase 2/3 presyncope 11.1% (placebo 0%) soft tissue injury 11.1% (placebo 0%) vomiting 11.1% (placebo 0%) NCT02881762 · Phase 4 · registry result, not featured evidence skin infection 22.2% upper respiratory infection 22.2% cerebrospinal fluid leakage 11.1% NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy nausea 11.7% respiratory tract infection 11.7% malaise 10.4% NCT01275625 · Phase 4 · registry result, not featured evidence · combination gastrointestinal intolerance 9.1% neuropsychiatric side effect 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination gastrointestinal intolerance 0% neuropsychiatric side effect 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination indirect hyperbilirubinemia (on atazanavir-based art) 8.7% (placebo 4.5%) prolonged fever 4.3% (placebo 0%) triglyceride elevation 4.3% (placebo 0%) NCT00735072 · Phase 4 · registry result, not featured evidence diarrhoea 16% nasopharyngitis 15.5% headache 10.7% NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy diarrhoea 9.1% bronchitis 6.5% headache 6.4% NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy BID diarrhoea 20.4% (placebo 20.9%) nausea 17.3% (placebo 18.7%) headache 15.7% (placebo 17.6%) NCT00098722 · Phase 2/3 · registry result, not featured evidence QD diarrhoea 26.9% (placebo 20.9%) nausea 21.4% (placebo 18.7%) headache 19.8% (placebo 17.6%) NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy BID injection site reaction 21% (placebo 14.8%) diarrhoea 19.4% (placebo 21.3%) headache 17.7% (placebo 8.2%) NCT00098748 · Phase 2/3 · registry result, not featured evidence QD diarrhoea 28.6% (placebo 21.3%) headache 20.6% (placebo 8.2%) nausea 14.3% (placebo 19.7%) NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy haemoglobin decreased 28.6% (placebo 22.9%) blood creatinine increased 24.5% (placebo 14.6%) blood glucose increased 16.3% (placebo 12.5%) NCT02741323 · Phase 2 · registry result, not featured evidence fatigue 30.8% cough 23.1% diarrhea 15.4% NCT01276236 · Phase 2 · registry result, not featured evidence hyperbilirubinaemia 30% diarrhoea 25% ocular icterus 21.7% NCT00827112 · Phase 2 · registry result, not featured evidence · combination headache 42.9% fever 14.3% joint pain 14.3% NCT01894776 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2/3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context differs: background therapy versus monotherapy.
- eThe assessment timepoint is not available for both results.
- fTrial phases differ: Phase 2 versus Phase 2/3.
- gTreatment context differs: combination versus background therapy.
- hAssessment timepoints differ: 16 weeks versus 1 weeks.
- iTreatment context differs: background therapy versus combination.
- jAssessment timepoints differ: 84 weeks versus 25 weeks.
- kTrial phases differ: Phase 3 versus Phase 2.
- lTreatment context has not been resolved for both arms.
- mPopulation comparability has not been reviewed for 6 of these studies.
- nPopulation comparability has not been reviewed for 23 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Leronlimab
show 2 more results
show 3 more results
show 2 more results
show 2 more results
+ 20 further endpoints in the CSV export.
Maraviroc
show 7 more results
show 7 more results
show 20 more results
show 1 more result
show 21 more results
show 22 more results
show 1 more result
show 1 more result
show 25 more results
show 6 more results
+ 45 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Leronlimab's landscape · Maraviroc's landscape